SOUTHLAKE, Texas, Oct. 10, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced participation in the following upcoming investor conferences: 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum, October 17-18, 2023Stifel 2023 Healthcare Conference,…Read More
Renibus Therapeutics Announces Participation at Upcoming Investor Conferences
